oral suspension is a dry mixture of erythromycin ethylsuccinate sulfisoxazole acetyl with suitable and harmless flavorings, buffers. surfactants, colorings, and suspending agents. When reconstituted as directed in the labeling, each milliliter will conerythromycin ethylsuccinate equivalent to 40 milligrams of erythromycin and sulfisoxazole acetyl equivalent to 120 milligrams of sulfisoxazole. Its erythromycin ethylsuccinate content is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of erythromycin that it is represented to contain. Its sulfisoxazole acetyl content is satisfactory if it is not less than 90 percent and not more than 115 percent of the number of milligrams of sulfisoxazole that it is represented to contain. Its loss on drying is not more than 1.0 percent. When reconstituted as directed in the labeling, its pH is not less than 5.0 and not more than 7.0. The erythromycin ethylsuccinate used conforms to the standards prescribed by §452.25(a)(1). The sulfisoxazole acetyl used conforms to the standards prescribed by the U.S.P.

- (2) Labeling. It shall be labeled in accordance with the requirements of § 432.5 of this chapter.
- (3) Requests for certification; samples. In addition to complying with the requirements of §431.1 of this chapter, each such request shall contain:
 - (i) Results of tests and assays on:
- (a) The erythromycin ethylsuccinate used in making the batch for potency, moisture, pH, residue on ignition, identity, and crystallinity.
- (b) The sulfisoxazole acetyl used in making the batch for all U.S.P. specifications.
- (c) The batch for erythromycin content, sulfisoxazole content, loss on drying, and pH.
 - (ii) Samples required:
- (a) The erythromycin ethylsuccinate used in making the batch: 10 packages each containing approximately 500 milligrams.
- (b) The batch: A minimum of 10 immediate containers.
- (b) Tests and methods of assay—(1) Erythromycin content. Proceed as directed in §436.105 of this chapter, preparing the sample for assay as follows:

Reconstitute the sample as directed in the labeling. Allow to stand for 1 hour. Shake gently and transfer 5 milliliters of the well-shaken suspension into a high-speed glass blender jar containing 195 milliliters of methyl alcohol. Blend for 3 to 5 minutes. Further dilute an aliquot with 0.1M potassium phosphate buffer, pH 8.0 (solution 3), to the reference concentration of 1.0 microgram of erythromycin base per milliliter (estimated).

- (2) Sulfisoxazole acetyl content. Proceed as directed in § 436.328 of this chapter
- (3) Loss on drying. Proceed as directed in §436.200(b) of this chapter.
- (4) pH. Proceed as directed in §436.202 of this chapter, using the suspension reconstituted as directed in the labeling.

[46 FR 2990, Jan. 13, 1981, as amended at 50 FR 19921, May 13, 1985]

§ 452.135 Erythromycin stearate oral dosage forms.

§452.135a Erythromycin stearate tablets.

- (a) Requirements for certification—(1) Standards of identity, strength, quality, and purity. Erythromycin stearate tablets are tablets composed of erythromycin stearate with suitable and harmless buffer substances, diluents, binders, lubricants, colorings, and flavorings. Each tablet contains erythromycin stearate equivalent to 75, 100, 125, 250, or 500 milligrams of erythromycin. Its potency is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of erythromycin that it is represented to contain. Tablets shall disintegrate within 11/2 hours. The loss on drying is not more than 5.0 percent. The erythromycin stearate used in making the tablets conforms to the standards prescribed by §452.35(a)(1).
- (2) Labeling. It shall be labeled in accordance with the requirements of § 432.5 of this chapter.
- (3) Requests for certification; samples. In addition to the requirements of §431.1 of this chapter, each such request shall contain:
 - (i) Results of tests and assays on:
- (a) The erythromycin stearate used in making the batch for potency, pH,